WATERS CORP /DE/ SEC Filings

Waters Corporation reported strong top-line growth for the quarter ended July 4, 2026, with net revenue of $1.645 billion, up from $771 million a year earlier. Organic revenue was $828 million versus $771 million, representing 7% organic reported growth and 9% in constant currency, while the recently acquired Biosciences and Diagnostic Solutions businesses contributed $817 million. By division, Analytical Sciences delivered $669 million, Biosciences $368 million, Advanced Diagnostics $521 million, and Materials Sciences $87 million.

Despite this growth, acquisition-related purchase accounting charges and other costs led to a GAAP diluted loss per share of $(1.39), compared with EPS of $2.47 in the prior-year quarter. Adjusted diluted EPS rose to $3.05 from $2.95. Operating cash flow for the quarter was $200 million and adjusted free cash flow was $202 million. The company raised full-year 2026 guidance, now expecting total revenue of $6.415–$6.476 billion and adjusted EPS of $14.45–$14.65, implying 7–9% organic constant currency revenue growth. Debt increased to $5.086 billion at July 4, 2026, reflecting financing for recent acquisitions, while total stockholders’ equity rose to $15.195 billion.

Waters Corp director Heather Knight reported a compensation-related equity award rather than a market trade. She acquired 63.03 common stock units of Waters common stock at a stated price of $0.00 per unit, bringing her direct holdings to 1,280.54 common stock units.

According to the disclosure, these common stock units were received in lieu of cash payment of director fees under the company’s 1996 Non-Employee Director Deferred Compensation Plan. The units are convertible into an equal number of Waters common shares upon distribution, which is scheduled to occur on January 1, 2027, based on a prior election.

Waters Corp director Wei Jiang reported a grant of common stock units received as board compensation. On this Form 4, Jiang acquired 67.42 common stock units at a stated price of $0.00 per unit, increasing direct holdings to 3,572.75 common stock units.

According to the filing, these units were received in lieu of cash payment of director fees under Waters Corp's 1996 Non-Employee Director Deferred Compensation Plan. Each common stock unit is convertible into one share of Waters Corp common stock upon distribution, which will occur automatically when Jiang's service on the board terminates.

Waters Corp SVP Robert L. Carpio III reported a routine tax-related share disposition. On June 24, 2026, 189 shares of Waters common stock were withheld by the company to cover tax obligations tied to the vesting of previously reported restricted stock units.

These shares were not sold on the open market but used to satisfy withholding requirements. After this transaction, Carpio directly holds 3,426 shares of Waters common stock.

Waters Corporation reported the results of its annual stockholder meeting, where approximately 90,729,508 shares, or about 92.4% of shares entitled to vote, were present or represented by proxy. Stockholders re-elected all nominated directors to the Board, with each candidate receiving a substantial majority of votes cast.

Stockholders also approved the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, they adopted a non-binding, advisory resolution approving the compensation paid to the company’s named executive officers.

Fundsmith LLP files Amendment No. 6 to a Schedule 13G/A reporting ownership of 4,308,930 shares of Waters Corp, representing 4.4%. The filing lists 4,294,850 shares as sole voting power and 4,308,930 as sole dispositive power. The filer certifies that the applicable foreign regulatory scheme is substantially comparable to the U.S. regime and offers to furnish Schedule 13D-equivalent information to Commission staff upon request.

Waters Corporation’s SVP & Chief Financial Officer Amol Chaubal reported a routine tax-related share disposition. On the reported date, 239 shares of common stock were withheld by the company to cover tax obligations tied to vesting of previously granted restricted stock units, rather than sold in the market.

After this withholding, Chaubal directly holds about 7,622.8449 common shares. This total includes 65.4519 shares acquired earlier through the Waters Corporation Amended and Restated 2009 Employee Stock Purchase Plan in a transaction described as exempt under Rule 16b-3(c), indicating ongoing equity participation.

Waters Corporation reports Q1 2026 results that fully reflect its acquisition of BD’s Biosciences & Diagnostic Solutions business. Revenue rose to $1,267 million from $662 million a year earlier, but Waters posted a net loss of $72 million versus prior net income of $121 million, driven by much higher costs and amortization.

The BDS Business Acquisition, structured as a Reverse Morris Trust, carried total consideration of about $12.96 billion, including 38,542 thousand new Waters shares and $4,000 million of assumed debt, and added $7,993 million of goodwill and $8,384 million of identifiable intangibles. Total assets increased to $24,531 million, while total debt rose to $5,215 million, including $3,500 million of new Senior Notes and a $500 million SpinCo Term Loan, materially increasing leverage as Waters integrates its expanded Biosciences and Advanced Diagnostics operations.